Findings

What do systematic reviews say?

2,532 questions · 2,642 findings · 483 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 534 · 20.2%GRADE not reported 82 · 3.1%Very low 641 · 24.3%Low 807 · 30.5%Moderate 472 · 17.9%High 106 · 4%

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placebo, on combination therapy

Physical functioning component of health‐related quality of life, measured using various scales · pulmonary arterial hypertension

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 267 participants
Moderate

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placebo, on combination therapy

PAP · pulmonary arterial hypertension

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 387 participants
High

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placebo, on combination therapy

Cardiac output · pulmonary arterial hypertension

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 310 participants
High

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placebo, on combination therapy

PVR · pulmonary arterial hypertension

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 303 participants
High

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs ERA

Improvement in WHO functional class · pulmonary arterial hypertension

Group 1 Pulmonary arterial hypertension ‐ PDE5i showed no clear difference in improvement in WHO functional class compared with ERA (moderate certainty).

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
OR 0.94 [0.55, 1.6]
1 study · 244 participants
Moderate

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs ERA

Six‐minute walk distance · pulmonary arterial hypertension

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 36 participants
Low

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs ERA

All‐cause mortality · pulmonary arterial hypertension

Group 1 Pulmonary arterial hypertension ‐ PDE5i showed no clear difference in mortality compared with ERA (moderate certainty).

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
OR 3.19 [0.74, 13.64]
2 studies · 272 participants
Moderate

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs ERA

Quality of life Kansas City Cardiomyopathy Quality‐of‐Life questionnaire (higher scores indicate better quality of life) · pulmonary arterial hypertension

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 25 participants
Low

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placebo

Six‐minute walk distance · pulmonary arterial hypertension

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
8 studies · 880 participants
Moderate

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs ERA

PAP · pulmonary arterial hypertension

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 11 participants
Low

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs ERA

RAP · pulmonary arterial hypertension

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 11 participants
Low

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs ERA

Cardiac index · pulmonary arterial hypertension

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 11 participants
Low

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs ERA

PVR · pulmonary arterial hypertension

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 11 participants
Low

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placebo

All‐cause mortality · pulmonary arterial hypertension

Group 1 Pulmonary arterial hypertension ‐ PDE5i leads to lower mortality compared with placebo (high certainty).

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
OR 0.22 [0.07, 0.68]
8 studies · 1119 participants
High

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placebo

QoL · pulmonary arterial hypertension

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 163 participants
GRADE not reported

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placebo

PAP · pulmonary arterial hypertension

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 453 participants
Moderate

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placebo

RAP · pulmonary arterial hypertension

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 341 participants
High

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placebo

Cardiac index · pulmonary arterial hypertension

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 239 participants
Moderate

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placebo

PVR · pulmonary arterial hypertension

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 266 participants
High

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placebo, on combination therapy

Improvement in WHO functional class · pulmonary arterial hypertension

Group 1 Pulmonary arterial hypertension ‐ PDE5i showed no clear difference in improvement in WHO functional class compared with placebo, on combination therapy (moderate certainty).

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
OR 1.2 [0.66, 2.17]
2 studies · 227 participants
Moderate